Search for European Projects

22 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Accelerated Early staGe drug diScovery (AEGIS)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia.The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cros ...
Read Project

 11

 FINISHED 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Read Project

 40

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 
IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Read Project

 20

 FINISHED 
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Read Project

 30

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Read Project

 39

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project

 33

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project

 32

 FINISHED 
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Read Project

 30

 FINISHED 
Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to the aging population, AMD has been referred to as a “time bomb” in society. In the exudative form of AMD, high levels of vascular endothelial cell growth factor (VEGF) and low levels of pigment-epithelial derived factor (PEDF), an inhibitor of vascularization a ...
Read Project

 16

 FINISHED 

European Medicines Research Training Network (EMTRAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Read Project

 32

 FINISHED 

Drug Disease Model Resources (DDMORE)

Start date: Mar 1, 2011, End date: Aug 31, 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project

 28

 FINISHED 

Electronic Health Record systems for Clinical Research (EHR4CR)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Read Project

 37

 FINISHED 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Read Project

 32

 FINISHED 
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Read Project

 23

 FINISHED 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Start date: Jun 15, 2009, End date: Jun 14, 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Read Project

 26

 FINISHED 
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Read Project

 20

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early develo ...
Read Project

 20

 FINISHED 
"Neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s disease (HD) still lack treatments that are disease modifying. The proposed network is going to address the three most important bottlenecks for finding more effective medicine in brain disorders. Those are: (i) identification and validation of pre-symptomatic and surrogate marker for disease progression, (ii) Develo ...
Read Project

 11

 FINISHED 

Continuous Annular Electro-Chromatography (CAEC)

Start date: Sep 1, 2008, End date: Aug 31, 2012,

Capillary electrochromatography (CEC) combines the high separation efficiency of capillary electrophoresis with high performance liquid chromatography (HPLC) and provides a powerful tool for the separation of a wide range of both neutral and charged components. The proposed integration of this technology and the rotating system of annular chromatography into a continuous annular electrochromatogra ...
Read Project

 8